Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 18

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 18
---
clinical development, is being investigated as a next-generation oral therapeutic targeting 
 metabolic regulation through CB1/CB2 receptor modulation and MAO-B inhibition, which play         
 key roles in appetite, metabolism, and energy balance.                                            |

| ● | SKNY-1                                                                                              
 is also being evaluated as a potential oral therapy for smoking cessation by modulating cannabinoid 
 signaling and dopamine metabolism, which are both implicated in nicotine dependence and addictive   
 behaviors.                                                                                          |

| ● | SKNY                                                                                           
 is a licensee of SKNY-1 under a license granted by MIRALOGIX LLC, a Florida limited liability  
 company. The license grants SKNY an exclusive right to make, use and sell SKNY-1 in the United 
 States, Canada and Mexico. The full text of the SKNY-1 Licensing Agreement is attached         
 as Annex E to this proxy statement.                                                            |

The Merger (see page 24) The Agreement and Plan of Merger, dated June 16, 2025 (“Merger Agreement”), was entered into by and among MIRA Pharmaceuticals, Inc., a Florida corporation, MIRAPHARM Acquisition Inc., a Delaware corporation and a wholly-owned subsidiary of MIRA (“Merger Sub”), and SKNY. Merger Sub will merge with and into SKNY, with Merger Sub being the surviving corporation (the “Merger”). Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein upon the consummation of the transactions contemplated by the Merger Agreement, Merger Sub will merge with and into SKNY, with SKNY continuing as the surviving corporation and a wholly-owned subsidiary of MIRA. As a result of the Merger, all of the issued and outstanding shares of common stock of SKNY, $0.0001 par value per share (“SKNY Common Stock”) immediately prior to the Effective Time shall no longer be outstanding and shall be exchanged for and automatically converted into the number of fully paid and nonassessable shares of MIRA Common Stock as calculated in accordance with the terms of the Merger Agreement. The Exchange Ratio is estimated to result in SKNY shareholders holding 50% of the issued and outstanding shares of MIRA Common Stock. Reasons for the Merger (see page 25) The MIRA Board considered various reasons for the Merger, as described later in this proxy statement under the section titled “ The Merger—Background of the Merger.” Fairness Opinion and Valuation Reports of Moore Financial Consulting (page 27) In